Key Highlights

  • aTyr Pharma (NASDAQ:ATYR) rose 16.90% to USD 5.78 in published market data around November 2, 2026, its first sessions after a 1-for-40 reverse split started trading on October 29, 2026.
  • The Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, published October 29, 2026 in The Lancet Respiratory Medicine, missed its primary steroid reduction endpoint at week 48.
  • The 5.0 mg/kg dose outperformed placebo on several patient-reported outcomes, lung function held steady and the drug was well tolerated. aTyr has also begun work on another global Phase 3 study.
  • The split cut shares outstanding from about 100.5 million to about 2.5 million, so USD 5.78 equals about USD 0.1445 before the split, simple arithmetic.

What Moved The Stock

Published market data around November 2, 2026 showed aTyr Pharma (NASDAQ:ATYR) up 16.90% at USD 5.78. The company filed a certificate of amendment on October 27 for a 1-for-40 reverse split, effective at 5:00 p.m. ET on October 28, with split-adjusted trading from the open on October 29. Stockholders had approved the split on October 16. The filing gives no reason, but reverse splits are commonly used to keep a share price above the Nasdaq minimum bid. Shares outstanding fell from about 100.5 million to about 2.5 million, so the Equity value is about USD 14.5 million at USD 5.78, simple arithmetic that ignores warrants and pre-funded warrants.

The Phase 3 Publication

The EFZO-FIT study enrolled 268 patients with moderate to severe pulmonary sarcoidosis and compared efzofitimod at 3.0 mg/kg and 5.0 mg/kg with placebo over 48 weeks, with a protocol guided steroid taper in the first 12 weeks. The primary endpoint, change in average daily oral corticosteroid dose at week 48, was not statistically significant. At 5.0 mg/kg, patients reported benefits on the King's Sarcoidosis Questionnaire lung and general health scores and on the Fatigue Assessment Scale. Forced vital capacity was maintained, and safety matched earlier trials. The publication presents data aTyr had already reported, so it is not new efficacy news.

Risks And Next Steps

A failed primary endpoint raises the bar for any further study, and secondary and patient-reported results can be hard to turn into a regulatory path. The company says it has recently started study related activities for a new global Phase 3 trial and continues the Phase 2 EFZO-CONNECT study in systemic sclerosis related interstitial lung disease. The release gave no cash figure or runway, so financing needs remain an open question for a company with about 2.5 million shares outstanding. With so few shares, a small number of trades can move the price, spreads can be wide and a quoted gain can reverse.

Where Things Stand

It is a volatile bounce, not a clear reversal. aTyr Pharma (NASDAQ:ATYR) rose 16.90% in its first sessions after a 1-for-40 reverse split, and the Phase 3 publication on October 29 added no new efficacy data after a missed primary endpoint. The positives are the 5.0 mg/kg patient-reported outcomes, maintained lung function and a planned new Phase 3. The negatives are the miss itself, the absence of a stated cash runway and a share count of about 2.5 million. Next evidence will come from the new trial design and any financing disclosure.